Severity Predictor of Respiratory InfectionsPatentedClinical validation

A diagnostic method predicting the severity of infectious disease symptoms days in advance. Using PCR-based detection of specific biomarkers in nasopharyngeal swabs, it identifies high-risk patients early, enabling timely therapy. Applicable to viral, bacterial, and fungal infections, it also monitors treatment efficacy. Optimized for large-scale testing. To develop the methodology and deliver a certified and proven test, GeneSpector decided to found a spin-off company called SeveriDx (www.severidx.com).

Pipeline

Product / technology
(target/biomarker)
Discovery stageDevelopmentScale-upCommercializationCommercial partner
Proof-of-conceptPre-clinic dataClinical validationCE / IVDRMarket
Severity Predictor
(RT-PCR / mRNA Biomarker)
Progress: 42 %

Project details

GeneSpector presents an innovative diagnostic method capable of predicting severity of symptoms of infectious diseases days prior to their manifestation.

Spread of Covid-19 uncovered a significant drawback in diagnostics of infectious diseases. Human immune response can cause more harm than the related infection itself, and therefore treatments based on symptoms may come too late.

Severity Predictor utilizes a PCR-based detection of a specific biomarker in nasopharyngeal swabs. Higher levels of the biomarker are detectable days prior to manifestation of symptoms of an already ongoing infectious disease and the values are dependent on severity of the upcoming symptoms. This method can be used in any PCR-capable laboratory and is fast and simple to perform.

The method allows an early assessment of high-risk patients and, if necessary, a timely application of a suitable therapy. It also allows a real-time observation of efficiency of the applied therapy, since the biomarker levels actively react on any development in the course of the disease and naturally decrease when the treatment is successful.

  • Severity Predictor is suitable not only for Covid-19, but for any infectious disease of viralbacterial, or fungal origin.
  • The method is fully developed and optimized for large-scale testing.

Contact

Do not hesitate
to contact us:

General queries,
investors & partners

info@genespector.com

 

US subsidiary

GeneSpector Innovations USA, Inc.
3500 South Dupont Highway
Dover DE 19901

EU subsidiary

GeneSpector s.r.o.
Petrska 1180/3
110 00 Prague, Czech Republic